
    
      This is a Phase III randomized, double-blind, parallel group, multi-center, 24-week lung
      function study with BFF MDI (320/9.6 μg and 160/9.6 μg) compared to FF MDI 9.6 μg, BD MDI 320
      μg, and open-label Symbicort® TBH (200/6 μg) administered BID. Subjects will undergo a 1- to
      4-week Screening Period. Subjects who successfully complete the Screening Period will be to
      one of the following five treatment groups:BFF MDI 320/9.6 μg BID (N=660), BFF MDI 160/9.6 μg
      BID, FF MDI 9.6 μg BID, BD MDI 320 μg BID, Symbicort®, TBH 400/12 μg BID. Following
      randomization, subjects will enter the Treatment Period and undergo additional treatment
      visits over 24 weeks.
    
  